PROTECT (2023) — Trial Summary

PROTECT (2023): The PROTECT phase 3 trial evaluated sparsentan, a dual endothelin type A and angiotensin II receptor antagonist, versus irbesartan in adults with IgA nephropathy at risk of progressive kidney function loss.

References

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.